Study to Evaluate CORT125134 in Patients With Cushing's Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02804750|
Recruitment Status : Recruiting
First Posted : June 17, 2016
Last Update Posted : June 19, 2017
Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol. Endogenous Cushing's syndrome resulting from cortisol overproduction by the adrenal glands is the subject of this protocol.
Patients with exogenous Cushing's syndrome, which develops as a side effect of chronic administration of high doses of glucocorticoids, are not eligible for enrollment in this study.
The purpose of this study is to evaluate the safety and efficacy of CORT125134 for treatment of endogenous Cushing's syndrome. The multicenter study will be conducted in the United States and in Europe.
|Condition or disease||Intervention/treatment||Phase|
|Cushing's Syndrome||Drug: CORT125134||Phase 2|
This is a Phase 2, open-label study with two dose groups, each with a two-step dose escalation, designed to evaluate the safety and efficacy of CORT125134 for the treatment of endogenous Cushing's syndrome. CORT125134 will be administered orally once daily for 12 weeks with dose escalations occuring every 4 weeks.
PK profiles will be generated at every dose level. A data review committee will review PK and safety data and will recommend the final plan for dose escalation in Group 2.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing's Syndrome|
|Study Start Date :||June 2016|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2017|
Group 1: 100 mg/day for 4 weeks, then 150 mg/day for 4 weeks, then 200 mg/day for 4 weeks.
Group 2: 250 mg/day for 4 weeks, then 300 mg/day for 4 weeks, then 350 mg/day for 4 weeks.
- General safety of CORT125134 in patients with endogenous Cushing's syndrome. [ Time Frame: 12 months ]The safety profile of CORT125134 in patients with Cushing's syndrome as assessed by physical examination findings, vital signs, ECG results, clinical laboratory tests, adverse events (CTCAE v4.0) and concomitant medications.
- The evidence of reduction in cortisol activity following treatment of CORT125134 in patients with endogenous Cushing's syndrome. [ Time Frame: 12 months ]The reduction in cortisol activity following treatment with CORT125134 in patients with endogenous Cushing's syndrome based on improvement in glucose control and/or blood pressure.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02804750
|Contact: Clinical Study Leadfirstname.lastname@example.org|
|United States, Colorado|
|Aurora, Colorado, United States, 80045|
|United States, Florida|
|Fort Lauderdale, Florida, United States, 33312|
|Miami, Florida, United States, 33136|
|United States, Indiana|
|Indianapolis, Indiana, United States, 46202|
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|United States, Pennsylvania|
|Pittsburgh, Pennsylvania, United States, 15212|
|United States, Virginia|
|Richmond, Virginia, United States, 23119|
|United States, Washington|
|Seattle, Washington, United States, 98122|
|Salford, Manchester, United Kingdom|
|Study Director:||Andreas G Moraitis, MD||Corcept Therapeutics|